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checkpoint inhibitors followed by UFT/LV can be useful for patients with left-sided
CRC.
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Background: The incidence of colorectal cancer in patients(pts) under the age of 50 has
been steadily on rising over the last two decades. This is in sharp contrast to average
onset CRC where there has been a decline. Little is known about clinical behavior and
biology of metastatic CRC in the growing YO population.
Methods: We defined YO as< 45 yo and AO as> 50 yo. To better understand the dif-
ferences in biology of early onset rectal tumors, we tabulated the clinical characteristics,
genomics using next generation sequencing(MSK-IMPACT), treatments and outcomes
in 175 metastatic pts with EO CRC, treated at Memorial Sloan Kettering Cancer Center
between 2014 and 2017 and compared these cases to a cohort of AO M CRC cases
(n¼ 413) with CRC related hereditary syndromes such as Lynch Syndrome and inflam-
matory bowel disease were excluded.
Results: We analyzed 175 in the YO cohort. Age at diagnosis was between 17-35yo in 46
and between 36-45 in 129 pts. Among YO patients, there were 50.2% males, 27.7%
smokers and the median BMI was 25.5. Comparing to AO, YO pts have significantly
less right sided tumors (22.8% vs 33%; p¼ 0.01). Treatment choices did not differ
among YO vs AO groups; systemic chemotherapy (46.7% vs 42.6%; p¼ 0.40) and
metastasectomy (54.6 vs 49.4; p¼ 0.33). Overall survival was 59months in the YO vs
63.9 for the AO (p¼ 0.194). Among genetic characteristics mutational burden and
copy number comparison showed no significant differences between the groups.
Conclusions: Our series describes a comprehensive clinical and genomic profile of EO
mCRC. In contrast to prior reports YO does not appear to be associated with more
aggressive disease and there was no difference in treatment modalities. Detailed
genomic and clinical characteristics will be presented.
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Background: Octogenarians have higher rates of comorbidity that are associated with a
poor prognosis. Few studies have identified prognostic factors of elderly patients (pts)
with colorectal cancer (CRC), so their optimized care strategies remain controversial.
Charlson comorbidity index (CCI) is the most widely used clinical scoring system to
predict the survival of patients with malignancies. The aim of this study was to investi-
gate the prevalence of comorbidity and the prognostic impact of the CCI score for sur-
vival among octogenarian pts with CRC in our center.
Methods: We reviewed 151 pts referred to Medical Oncology between January 2012
and March 2017. Data on demographics, staging, treatment and survival were collected
and analysed. CCI score was independent variable. OS rates was estimated by the
Kaplan–Meier method, with differences in survival between groups compared by the
log-rank test.
Results: We reviewed 151 pts with CRC referred to Medical Oncology between January
2012 and March 2017. Data on demographics, staging, treatment and survival was col-
lected and analysed. CCI score was the independent variable. OS rates was estimated by
the Kaplan–Meier method, with differences in survival between groups compared by
the log-rank test. Results Octogenarians were a 19% of all pts, 82 (54%) men and 69
(46%) women. The median age was 84 years. There was no difference in performance
status (PS) between genders with PS 0-1 in 76%, PS 2 in 26% and PS 3-4 in 10%. Pts
were divided into high CCI score (CCI 3; n¼ 52) and low CCI score (CCI< 3;
n¼ 99) groups for comparative analyses of differences in their short- and long-term
outcomes. The overall survival (OS) in pts with a Low CCI Score was longer than that
in high CCI score (46 versus 25 months; p< 0.01). High CCI score significantly relates









Sex (male/female) 46/53 23/29 0.74
Stage at diagnosis I II III IV 10 21 39 29 6 7 16 23 0.003
Primary tumor location Right Left Rectum 38 44 17 24 17 11 0.24
Conclusions: In our study CCI score (low or high) showed be independent factor in
prognosis and survival in octogenarian patients with colorectal cancer.
Funding: Has not received any funding.
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Background: Aging induces meaningful changes in immune system and inflammation
response with increase in monocyte-lymphocyte ratio (MLR) and serum lactate dehy-
drogenase (LDH) levels. Notably, high levels of these serum biomarkers are associated
with poor prognosis in many tumors. We aim to explore the prognostic role of baseline
(i.e. before first line chemotherapy) MLR and LDH levels in elderly patients (pts) with
metastatic colorectal cancer (MCRC).
Methods: A retrospective analysis of a consecutive cohort of 120 elderly (>70 years) pts
treated for MCRC between 2004 and 2017 at the Oncology Department of Aviano
National Cancer Institute and University Hospital of Udine (Italy), was conducted.
The prognostic role of MLR and LDH levels on overall survival (OS) was investigated
through uni- and multivariate Cox regression analyses.
Results: At a median follow-up of 50.83 months, median OS was 19.96 months.
Overall, 46 pts (38%) presented a right cancer, 43 pts (36%) a left cancer and 30 pts
(25%) a rectal one. In 8 (8%) and 47 (50%) pts a mutation of BRAF or KRAS was
detected, respectively. Liver (36%), lymph-nodes (22%), peritoneum (22%) and lung
(17%) were the most frequent sites of metastasis. Noteworthy, 22 pts (18%) had under-
gone a metastasectomy. High levels of LDH (>480 U/L) and MLR (>0.45, obtained
with ROC curve) were discovered in 23 (32%) and 51 (42%) patients respectively. By
univariate analysis, high levels of LDH (HR 2.81, p¼ 0.001), MLR (HR 2.26, p< 0.001)
or both (HR 6.42, p< 0.001) and node involvement at diagnosis (pN2 vs. pN0 HR 2.15,
p¼ 0.019; pN3 vs. pN0 HR 2.69, p¼ 0.052) were associated with worse OS.
Metastasectomy (HR 0.47, p¼ 0.009), tumor resection (HR 0.50, p¼ 0.010) and left
sidedness (HR 0.53, p¼ 0.01) were associated with better OS. By multivariate analysis,
high levels of LDH (HR 2.64, p¼ 0.004), MLR (HR 2.21, p¼ 0.009) or both (HR 4.19,
p¼ 0.019) were independently associated with worse OS.
Conclusions: High baseline levels of LDH, MLR or both are unfavorable independent
prognostic factors in elderly pts treated with first line chemotherapy for MCRC. These
preliminary results emphasize the need of prospective studies to validate these cost-
effectiveness biomarkers in this subgroup of pts.
Legal entity responsible for the study: University of Udine.
Funding: Has not received any funding.
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Background: Overall survival of patients (pts) with metastatic colorectal cancer
(mCRC) has been increasing over the last decades. “Drug holiday” strategies were
introduced by the oncologists to reduce toxicity. We aimed at studying what are the
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clinico-pathological and treatment factors that drive the decision to propose a “drug
holiday” in first line.
Methods: This is a retrospective series of consecutive pts affected by mCRC treated
with first line chemotherapy. The pts included were treated from 1/1/2005 to 15/03/
2017 at University Hospital of Udine and IRCCS CRO of Aviano, Italy. A “drug
Holiday” was defined as 56 or more consecutive days without chemotherapy during
first-line. Upfront metastasectomy were excluded. Logistic regression was used to find
association between predictors and “holiday offer” in univariate and multivariate
analysis.
Results: A total of 648 pts were included. In detail, 215 received a drug holiday (33.2%)
while 433 (66.8%) received continuous treatment. In univariate analysis, the variables
associated with holiday were: non-upfront metastasectomy (OR 11.8, IC 95% 6.62-
22.6, p< 0.001), thermoablation (OR 6.08, IC 95% 3.19-11.58, p< 0.001), primary
tumor (OR 2.79, IC 95% 1.79-4.34, p< 0.001), G3-G4 pathological grade (OR 1.49, IC
95% 1.01-2.19, p¼ 0.046), adjuvant CT (OR 1.54,IC 95% 1.06-2.33, p¼ 0.023).
Adjuvant RT (OR 1.62, IC 95% 0.99-2.62, p¼ 0.051) showed a trend towards associa-
tion. More than one metastatic site at diagnosis (OR 0.59, IC 95% 0.42-0.83, p¼ 0.003)
and nodal involvement (OR 0.57, IC 95%, 0.34-0.95, p¼ 0.032) were associated to con-
tinuous treatment. In multivariate analysis, only first line non-upfront metastasectomy
(OR 9.89, IC95% 4.38-22.33, p< 0.001), thermoablation (OR 4.48, IC95% 1.97-10.19,
p< 0.001) and primary tumor resection (OR 2.43, IC95% 1.14-5.19, p¼ 0.022) were
independently associated with drug-holiday.
Conclusions: In our cohort, clinicians were more prone to propose a drug holiday in
pts who had received non-upfront metastasectomy or thermo-ablation or were treated
on their primary tumor. Having more than one site of metastasis at the beginning of 1st
line and nodal involvement favored continuous therapy.
Legal entity responsible for the study: ASUIUD- Azienda Ospedaliero-Universitaria
di Udine, Dipertimento di Oncologia.
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Background: Cetuximab and panitumumab, monoclonal antibodies direct against the
epidermal growth factor receptor (EGFR) are a therapeutic option for mCRC patients
wild type for KRAS and NRAS genes. However, only a subset of mCRC patients receives
clinical benefit from these therapies due to the development of resistance mechanisms.
HER2 gene amplification or HER2 activating mutations have been implicated as resist-
ance mechanisms to anti-EGFR therapies. However, little is known about the role of
HER2 in cancer resistance to anti-EGFR antibodies.
Methods: We transfected colon cancer cells sensitive to anti-EGFR antibodies
(LIM1215 and SW48) with HER2 vector in order to obtain stable clones overexpressing
HER2 protein. LIM1215-HER2 and SW48-HER2 cells were characterized by their mor-
phological and molecular profile through cell migration and WB assays. Moreover, dif-
ferent drugs sensitivity was evaluated by MTT and colony formation. Furthermore,
HER2 amplified cells were engrafted into nude mice and treated with different drugs.
Results: HER2 amplified cells show an overexpression and activation of the HER family
receptors coupled by an intracellular downstream activation pathway of AKT, MAPK,
and MEK proteins compared to parental cells. HER2 amplified cells were treated with
several combinations of drugs directed against HER receptors, such as anti-EGFR anti-
bodies of first, second and third generation (cetuximab, SYM004 and MM151); trastu-
zumab, pertuzumab and lapatinib directed against HER2 receptor; and duligotuzumab
direct against HER3. Subsequently, both cells were treated with drugs directed against
MEK and PI3KCA proteins, such as refametinib and pictilisib. Among these therapeu-
tic options, the combination of refametinib and pictilisib have shown the most syner-
gist anti-proliferative activity. The in vivo xenograft CRC models have confirmed the
synergistic antitumor activity of this combined treatment. Moreover, PDTX HER
amplified CRC models will be used to validate the previous results.
Conclusions: These results suggest that the treatment with refamentinib and pictilisib
could be a strategy for patients with HER2 amplification that do not receive clinical
benefit from standard anti-EGFR therapies.
Legal entity responsible for the study: Universita Degli Studi della Campania Luigi
Vanvitelli.
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Background: The treatment of cancer may be improved by testing the chemo sensitiv-
ity of cancer cells obtained from the patient’s tumor. 3D culture represents a promising
method for modeling of patient tumors in vitro. The purpose of this study was to test
the feasibility of a clinical trial offering patients with metastatic colorectal cancer treat-
ment based on in-vitro testing anti-cancer therapy sensitivity.
Methods: Main inclusion criteria were stage IV colorectal cancer, PS 0-1, previous
exposure to 5FU, oxaliplatin, irinotecan, bevacizumab and, if RAS/RAF wild-type, an
EGFR inhibitor. Fresh cancer tissues from metastases were cultivated as tumoroids.
The culturing protocol which was originally developed for resected tissue was opti-
mized for the smaller tissue amounts received from needle biopsies. Ten patients were
to be included and at least five of them to have clinically applicable results in order for
the procedure to be feasible.
Results: Ten patients were included from September to December 2017 in one institu-
tion. Biopsies were from liver (6), peritoneum (2), retroperitoneum (1) and lung (1).
Rebiopsies were allowed and a total of 19 biopsy sessions were performed with ultra-
sound (14), CT (3) or sigmoidoscopy (2). In seven cases, the biopsy, tumorsphere for-
mation and sensitivity testing was successful. Median time from biopsy to result was 34
days (range 19-50). A notable challenge was obtaining sufficient viable tumor tissue
resulting in increased culture times or the need for re-biopsies.
Conclusions: This is the first clinical study of its kind. The method of selecting last-line
treatment of colorectal cancer based on fresh biopsies was feasible as results were
obtained in seven out of ten cases. The trial is now extended to a phase II trial with PFS
as the primary endpoint.
Clinical trial identification: NCT03251612.
Legal entity responsible for the study: Lars Henrik Jensen.
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Background: The anti-epidermal growth factor receptor (EGFR) monoclonal antibod-
ies (mAbs) cetuximab and panitumumab are effective in a subset of RAS/BRAF wild-
type (WT) metastatic colorectal cancers (mCRCs) patients. Despite an accurate RAS-
driven selection, not all patients will respond to EGFR inhibitors and the onset of sec-
ondary resistance limits their clinical benefit.
Methods: With the aim of developing effective preclinical models for testing possible
strategies to overcome acquired resistance to EGFR blockade, we have generated a series
of human colon cancer cell lines with in vitro and in vivo acquired resistance to anti-
EGFR inhibitors. To better investigate the differentially expressed proteins involved in
EGFR resistance, we applied an advanced quantitative proteomic approach based on
TMT isobaric labeling and nano-liquid chromatography coupled with high resolution
tandem mass spectrometry (MS/MS).
Results: To evaluate changes in protein expression we have used human CRC cell line
cetuximab-sensitive GEO, as well as its derived cell line with acquired resistance to
cetuximab GEO-CR. By MS/MS, we have identified and quantified 2455 proteins; 53
proteins were found to be differentially expressed in GEO-CR compared to GEO cells.
Only 11 proteins were found to be high regulated in GEO-CR, among these we focused
our attention on the inhibition factor of macrophage migration (MIF) for its relevance
in CRC tumorigenesis. To explore its involvement in resistance to cetuximab in CRC
cell line, we have performed an MTT assay with two MIF-antagonists, ISO1 a cell-per-
meable inhibitor of MIF tautomerase and 4-IPP, a selective MIF inhibitor that blocks
MIF and its receptor, CD74, internalization. GEO-CR cell line was treated with two
MIF antagonists alone and in combination with cetuximab. Only the combined treat-
ment with cetuximab and 4-IPP induced a synergistic antiproliferative and apoptotic
effects.
Conclusions: These results suggest that MIF overexpression is involved in acquired
resistance to cetuximab and the inhibition of EGFR and MIF could be a strategy for
overcoming anti-EGFR resistance in patients with CRC.
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